Zobrazeno 1 - 10
of 15
pro vyhledávání: '"John Iuliucci"'
Autor:
Victor M. Rivera, Roy M. Pollock, Lori Berk, Frank Wang, Narayana I. Narasimhan, Tim Clackson, Rachel M. Squillace, Scott Wardwell, David Miller, John Iuliucci, Yaoyu Ning
Publikováno v:
Molecular Cancer Therapeutics. 10:1059-1071
The mTOR pathway is hyperactivated through oncogenic transformation in many human malignancies. Ridaforolimus (AP23573; MK-8669) is a novel rapamycin analogue that selectively targets mTOR and is currently under clinical evaluation. In this study, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54de8509cf2d7c8d3fe132c6ec5268a
https://doi.org/10.1158/1535-7163.mct-10-0792
https://doi.org/10.1158/1535-7163.mct-10-0792
Autor:
Xiaotian Zhu, Dong Zou, Chester A. Metcalf, Raji Sundaramoorthi, Frank Wang, Feng Li, Jan Romero, John Iuliucci, Lois Commodore, Shuangying Liu, Wei-Sheng Huang, Lisi Cai, Qihong Xu, Jeff Keats, Tim Clackson, David C. Dalgarno, Joseph Snodgrass, Jiwei Qi, Yihan Wang, Victor M. Rivera, Mathew Thomas, Ingrid Chen, Tianjun Zhou, Yaoyu Ning, David Wen, Tomi K. Sawyer, Karin Russian, William C. Shakespeare, Marc I Broudy, Scott Wardwell
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:3743-3748
Ponatinib (AP24534) was previously identified as a pan-BCR-ABL inhibitor that potently inhibits the T315I gatekeeper mutant, and has advanced into clinical development for the treatment of refractory or resistant CML. In this study, we explored a nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a38549836ca328c6bb343c0b0ec0da
https://doi.org/10.1016/j.bmcl.2011.04.060
https://doi.org/10.1016/j.bmcl.2011.04.060
Autor:
Yaoyu Ning, Chester A. Metcalf, Lois Commodore, Jan Romero, Scott Wardwell, Tomi K. Sawyer, Yihan Wang, Qurish K. Mohemmad, Scott Paul Lentini, Ingrid Chen, Victor M. Rivera, Karin Russian, Geetha Banda, Sasmita Das, Narayana I. Narasimhan, Xiaotian Zhu, Raji Sundaramoorthi, Lisi Cai, Tianjun Zhou, Jeff Keats, Frank Wang, Tim Clackson, Qihong Xu, Jiwei Qi, David Wen, Joseph Snodgrass, Shuangying Liu, William C. Shakespeare, R. Mathew Thomas, Marc I Broudy, John Iuliucci, Wei-Sheng Huang, David C. Dalgarno, Dong Zou
Publikováno v:
Journal of Medicinal Chemistry. 53:4701-4719
In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents. This report describes the structure-guided design of a novel series of potent pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::757a483ca43d6a44106283733dc26b6a
https://doi.org/10.1021/jm100395q
https://doi.org/10.1021/jm100395q
Autor:
Jeff Keats, Marc I Broudy, John Iuliucci, Scott Wardwell, Karin Russian, Sasmita Das, Yaoyu Ning, Scott Paul Lentini, Yihan Wang, David Wen, William C. Shakespeare, Joseph Snodgrass, Tomi K. Sawyer, David C. Dalgarno, R. Mathew Thomas, Xiaotian Zhu, Mohammad Azam, Shuangying Liu, George Q. Daley, Wei-Sheng Huang, Raji Sundaramoorthi, Tim Clackson, Geetha Banda, Qihong Xu, Frank Wang
Publikováno v:
Journal of Medicinal Chemistry. 52:4743-4756
A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c4c8fc144dc20cf0e38dd91c2a9789
https://doi.org/10.1021/jm900166t
https://doi.org/10.1021/jm900166t
Autor:
Selvi Pradeepan, Chet Metcalf, Brendan F. Boyce, Shuangying Liu, Manfred Weigele, Surinder S. Narula, Regine S. Bohacek, Lianping Xing, Raji Sundaramoorthi, Jeff Keats, Julie Bogus, Jennifer Saltmarsh, Yihan Wang, Scott Wardwell, Mary K. Ram, David C. Dalgarno, John Iuliucci, Susan Adams, Guru Paramanathan, Shuenn Liou, Marie Rose van Schravendijk, Anne Dilauro, Sonya Roeloffzen, T. Keenan, William C. Shakespeare, Tomi K. Sawyer
Publikováno v:
Chemical Biology & Drug Design. 71:97-105
Targeted disruption of the pp60(src) (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Here, we describe structure acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dcdeae0a92758c4ad04f2c1f5760a13
https://doi.org/10.1111/j.1747-0285.2007.00615.x
https://doi.org/10.1111/j.1747-0285.2007.00615.x
Autor:
David C. Dalgarno, Tim Clackson, Stanley R. Riddell, C. Anthony Blau, Joëlle Gaschet, Carolina Berger, John Iuliucci, Shelly Heimfeld, Meei Li Huang
Publikováno v:
Blood. 103:1261-1269
Conditional suicide genes derived from pathogens have been developed to confer drug sensitivity and enhance safety of cell therapy, but this approach is limited by immune responses to the transgene product. We examined a strategy to regulate survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f94d5322d300963526e2a20a5f3068a
https://doi.org/10.1182/blood-2003-08-2908
https://doi.org/10.1182/blood-2003-08-2908
Publikováno v:
Expert Opinion on Investigational Drugs. 10:1327-1344
Following the milestone discoveries that identified Src as the first known protein tyrosine kinase and as a prototype oncogene, as well as Src transgenic studies to validate it as a promising therapeutic target for osteoporosis, intense efforts are b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::304887e359c31ef3c9773175fa56bb83
https://doi.org/10.1517/13543784.10.7.1327
https://doi.org/10.1517/13543784.10.7.1327
Autor:
Zhenqiang Yao, Yihan Wang, Tomi K. Sawyer, Raji Sundaramoorthi, Brendan F. Boyce, David C. Dalgarno, Chester A. Metcalf, Lianping Xing, William C. Shakespeare, John Iuliucci
Publikováno v:
Annals of the New York Academy of Sciences. 1068
Understanding of the regulation of bone catabolism has advanced significantly over the past two decades with the identification of key enzymes that regulate osteoclast formation, activation, and survival following their knockout in mice or recognitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74a82b08116934624b34589c12fd7f1c
https://pubmed.ncbi.nlm.nih.gov/16831942
https://pubmed.ncbi.nlm.nih.gov/16831942
Autor:
Chester A. Metcalf, Shadmehr Demehri, Amie S. Corbin, Michael Heinrich, John Iuliucci, Yihan Wang, Ian J. Griswold, William C. Shakespeare, Raji Sundaramoorthi, Scott Wardwell, Joseph Snodgrass, David C. Dalgarno, Tomi K. Sawyer, Brian J. Druker, Michael W. Deininger
Publikováno v:
Blood. 106(1)
Oncogenic mutations of the Kit receptor tyrosine kinase occur in several types of malignancy. Juxtamembrane domain mutations are common in gastrointestinal stromal tumors, whereas mutations in the kinase activation loop, most commonly D816V, are seen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677e77a40abf06fe98c60c0a5760f27e
https://pubmed.ncbi.nlm.nih.gov/15746079
https://pubmed.ncbi.nlm.nih.gov/15746079
Autor:
Chad Haraldson, Taylor Merry, Tomi K. Sawyer, Karin Stebbins, Marcos Hatada, Franklin Cerasoli, Surinder S. Narula, David C. Dalgarno, William C. Shakespeare, Marie Rose van Schravendijk, Jay Herson, Selvi Pradeepan, John Iuliucci, Manfred Weigele, Raji Sundaramoorthi, Xiaode Lu, Jeremy Smith, Mihai Azimioara, Susan Adams, Chester A. Metcalf, Shelia Violette, Chi B. Vu, Regine S. Bohacek, Michael Yang, Wei Guan, Catherine Bartlett
Targeted disruption of the pp60 src (Src) gene has implicated this tyrosine kinase in osteoclast-mediated bone resorption and as a therapeutic target for the treatment of osteoporosis and other bone-related diseases. Herein we describe the discovery
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4c5b835f12945cdcdbb7f6a31d14980
https://europepmc.org/articles/PMC16871/
https://europepmc.org/articles/PMC16871/
